STOCK TITAN

LeonaBio Q3 2026 net loss widens to $21.2M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

LeonaBio, Inc. (LONA) reported a third-quarter net loss of $21.2 million, or $0.89 per share, compared with a net loss of $6.6 million, or $1.68 per share, a year earlier. Cash, cash equivalents and investments totaled $32.3 million as of September 30, 2026, versus $88.3 million as of December 31, 2025. Net cash used in operations was $18.98 million, compared with $4.7 million in the year-earlier quarter.

LeonaBio targets completing enrollment in its Phase 3 ELAINE-3 trial of lasofoxifene with abemaciclib in the fourth quarter of 2026 and expects topline data in the second half of 2027. Its Phase 1 study of brelgometon enrolled 80 healthy volunteers; the company reported favorable safety and tolerability, dose-proportional pharmacokinetics and central nervous system penetration. It expects to update the timing of a proposed Phase 2 brelgometon trial after ELAINE-3 enrollment is complete.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

2 major · 2 points

How the balance works

Positive

  • None.

Negative

  • Major pointQuarterly net loss reached $21.2 million, compared with $6.6 million a year earlier.
  • Major pointNet cash used in operations was $18.98 million, compared with $4.7 million a year earlier.

Filing Explained

The September 30, 2026 balance sheet lists no amount for the Sermonix pre-funded warrant liability, compared with $37,488 thousand at December 31, 2025.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Net loss $21.2 million Quarter ended September 30, 2026; compared with $6.6 million for the quarter ended September 30, 2025
Net loss per share $0.89 per share Quarter ended September 30, 2026; compared with $1.68 per share for the quarter ended September 30, 2025
Cash, cash equivalents and investments $32.3 million As of September 30, 2026; compared with $88.3 million as of December 31, 2025
Net cash used in operations $18.98 million Quarter ended September 30, 2026; compared with $4.7 million for the quarter ended September 30, 2025
Median progression-free survival Approximately 13 months ELAINE-2 study of lasofoxifene with abemaciclib
Objective response rate 56% ELAINE-2 study of lasofoxifene with abemaciclib
Clinical benefit rate 65.5% ELAINE-2 study of lasofoxifene with abemaciclib
Phase 1 healthy volunteers 80 Brelgometon study
selective estrogen receptor modulator medical
"nonsteroidal selective estrogen receptor modulator (SERM)"
A selective estrogen receptor modulator (SERM) is a type of medication that acts like a targeted switch for the body's estrogen system, boosting estrogen-like effects in some tissues (for example bone) while blocking them in others (for example breast or uterus). For investors, SERMs matter because they represent drug candidates or marketed therapies whose safety profile, regulatory approval, patent protection and market size can heavily influence a company’s revenue prospects and risk profile.
CDK4/6 inhibitor medical
"abemaciclib, a CDK4/6 inhibitor"
A CDK4/6 inhibitor is a type of cancer drug that blocks two proteins (CDK4 and CDK6) that tell cells to divide, effectively slowing or stopping the growth of tumors. Think of it as cutting power to a photocopier that keeps making cancer cells; that control can shrink tumors or delay progression. For investors, these drugs matter because clinical trial results, regulatory approvals, patent life, safety issues and competition directly affect sales potential and company value.
progression free survival medical
"primary endpoint of the study"
Progression free survival is the length of time during and after a treatment when a disease, such as cancer, does not get worse or spread. It is an important measure because longer periods of stability can indicate that a treatment is effectively controlling the condition. For investors, it provides insight into the potential durability and success of a therapy or medication.
blinded, independent central review medical
"as determined by blinded, independent central review"
A blinded, independent central review is a process in clinical trials where an outside group of experts, who do not know which treatment each patient received, re-examines key trial data (often medical images or outcome measurements) to confirm results. Think of it like neutral referees watching game footage to verify scores; it reduces bias and variability across sites, so trial results are seen as more reliable and credible to regulators, analysts, and investors.
objective response rate medical
"an objective response rate of 56%"
The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug’s ability to produce a clear treatment effect—like counting how many plants visibly respond after applying a new fertilizer—and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.
dose-proportional pharmacokinetics medical
"dose-proportional pharmacokinetics and CNS penetration"
Net loss $21.2 million Compared with a net loss of $6.6 million for the quarter ended September 30, 2025.
Net loss per share $0.89 per share Compared with $1.68 per share for the quarter ended September 30, 2025.
Cash, cash equivalents and investments $32.3 million Compared with $88.3 million as of December 31, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much cash and investments did LONA report at September 30, 2026?

LeonaBio reported $32.3 million in cash, cash equivalents and investments as of September 30, 2026. The corresponding amount was $88.3 million as of December 31, 2025.

When does LONA expect ELAINE-3 results?

LeonaBio targets completing enrollment in ELAINE-3 in the fourth quarter of 2026 and expects topline data in the second half of 2027. The Phase 3 trial evaluates lasofoxifene in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer.

What results did LONA report from the ELAINE-2 study?

LeonaBio reported that ELAINE-2 showed a median progression-free survival of approximately 13 months, an objective response rate of 56% and a clinical benefit rate of 65.5%. The open-label study evaluated lasofoxifene with abemaciclib in heavily pretreated patients.

What is the primary endpoint of LONA's ELAINE-3 trial?

ELAINE-3's primary endpoint is a statistically significant improvement in progression-free survival, as determined by blinded, independent central review.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false000162046300016204632026-11-162026-11-16

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2026

 

LeonaBio, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

001-39503

45-3368487

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

18706 North Creek Parkway, Suite 104
Bothell, WA 98011

(Address of principal executive offices, including zip code)

 

(425) 620-8501

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

LONA

The Nasdaq Stock Market LLC 
(The Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act). ☐

 

 

 

 


 

Item 2.02 Results of Operations and Financial Condition.

On November 16, 2026, LeonaBio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.

Item 7.01 Regulation FD Disclosure.

 

The Company announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, the Company’s website (www.leonabio.com), its investor relations website (investors.leonabio.com), and its news site (investors.leonabio.com/news-and-events/press-releases). The Company uses these channels, as well as social media, including its X account (@leonabioinc), LinkedIn account (www.linkedin.com/company/leonabio), Instagram account (@leona.bio) and Facebook page (www.facebook.com/leonabioinc/), to communicate with investors and the public about the Company, its product candidates, and other matters. Therefore, the Company encourages investors, the media, and others interested in the Company to review the information it makes public in these locations, as such information could be deemed to be material information.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.

 

Description

99.1

 

LeonaBio, Inc. press release dated November 16, 2026

 

 

 

104

 

Cover Page Interactive Data File (formatted as Inline XBRL)

 

The information furnished in this Current Report under Items 2.02 and 7.01 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

LeonaBio, Inc.

 

 

 

 

Date:

November 16, 2026

By:

/s/ Mark Litton

 

 

 

Mark Litton

 

 

 

President and Chief Executive Officer

 

 

 

 


Exhibit 99.1

 

 

LeonaBio Reports Third Quarter 2026 Financial Results and Provides Business Update

 

On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected in 2H 2027


 

BOTHELL, Wash., November 16, 2026 – LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today reported financial results for the quarter ended September 30, 2026, and provided recent pipeline and business updates.

 

“We continue to execute with focus and discipline as we advance ELAINE-3 and target completion of enrollment in the fourth quarter of 2026,” said Mark Litton, Ph.D., President and Chief Executive Officer of LeonaBio. “With enrollment nearing completion, we are entering a pivotal phase in the development of lasofoxifene. Our efforts extend beyond clinical execution as we advance regulatory, manufacturing and commercial readiness activities designed to support a potential launch and maximize the opportunity to bring this important therapy to patients as efficiently as possible.”

 

“We believe lasofoxifene has the potential to redefine treatment for patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, a population that continues to face disease progression despite advances in care. The compelling body of clinical and scientific evidence generated to date, including encouraging efficacy and tolerability findings from our Phase 2 studies, reinforces our confidence in the program and its potential to become a new standard of care.” added Dr. Litton.

 

Clinical Development & Pipeline Programs

 

Lasofoxifene – A third generation novel, nonsteroidal selective estrogen receptor modulator (SERM) with a unique binding profile, designed to confer potent activity against both wild-type and mutant estrogen receptors, including the clinically significant ESR1 mutations commonly associated with resistance to endocrine therapy in metastatic breast cancer.

 

•
Lasofoxifene is being advanced in ELAINE-3, a Phase 3 clinical trial (NCT05696626), in combination with abemaciclib, a CDK4/6 inhibitor, as a targeted therapy for estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated metastatic breast cancer, following progression on aromatase inhibitors and CDK4/6 inhibitors. The primary endpoint of the study is a statistically significant improvement in progression free survival (PFS), as determined by blinded, independent central review (BICR). ELAINE-3 aims to establish a new standard of care for this genetically defined patient group with limited treatment options.
•
Lasofoxifene was previously evaluated in two Phase 2 studies in patients with ER+, HER2-negative locally advanced or metastatic breast cancer expressing an ESR1 mutation, ELAINE-1 and ELAINE-2.
o
ELAINE-1, an open-label, randomized trial comparing lasofoxifene to fulvestrant, showed improved outcomes for lasofoxifene as a potential monotherapy. Although the trial was

 

not powered, results included longer median progression-free survival (5.6 vs. 3.7 months), higher objective response rates (13.3% vs. 2.9%) and a durable complete response lasting more than 2.5 years. The treatment was well-tolerated with patients reporting quality-of-life benefits.
o
ELAINE-2, an open-label study evaluating lasofoxifene in combination with abemaciclib, demonstrated clinical benefits in heavily pretreated patients, with a median progression-free survival of approximately 13 months, an objective response rate of 56% and a clinical benefit rate of 65.5%. The combination was generally well-tolerated with most adverse events being low grade.
•
In April 2026, LeonaBio hosted a virtual Key Opinion Leader event with two leading physicians in the breast cancer field to discuss the current and evolving treatment landscape in metastatic breast cancer and the potential for lasofoxifene to transform the standard of care for patients with treatment-resistant ER+, HER2-negative, ESR1-mutated metastatic breast cancer.
o
The event featured a discussion with David Portman, M.D., Chief Executive Officer of Sermonix Pharmaceuticals and an oncology consultant to LeonaBio, along with two physician experts in the breast cancer field. A replay of the event is available on the LeonaBio website under “Events & Presentations” in the “Investor Relations” section here.

 

 

Brelgometon (ATH-1105) – A novel, orally available, brain-penetrant, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and Parkinson’s disease. Brelgometon is currently in clinical development for the potential treatment of ALS.

 

•
LeonaBio’s first-in-human Phase 1 double-blind, placebo-controlled clinical trial (NCT06432647) enrolled 80 healthy volunteers to evaluate single and multiple oral ascending doses of brelgometon, demonstrating a favorable safety and tolerability profile as well as dose-proportional pharmacokinetics and CNS penetration and supporting its advancement into a Phase 2 proof-of-concept trial.
•
The Company expects to provide an update on the timing of a proposed Phase 2 proof-of-concept clinical trial following completion of enrollment of the Phase 3 ELAINE-3 clinical trial as it continues to focus on its lasofoxifene program.

 

Financial Results

 

•
Cash Position. Cash, cash equivalents and investments were $32.3 million as of September 30, 2026, compared to $88.3 million as of December 31, 2025. Net cash used in operations was $18.98 million for the quarter ended September 30, 2026, compared to $4.7 million for the quarter ended September 30, 2025.
•
Research and Development (R&D) Expenses. R&D expenses were $14.6 million for the quarter ended September 30, 2026, compared to $2.8 million for the quarter ended

 

September 30, 2025. The increase was driven primarily by clinical trial spend related to the ELAINE-3 trial for lasofoxifene.
•
General and Administrative (G&A) Expenses. G&A expenses were $6.9 million for the quarter ended September 30, 2026, compared to $4.0 million for the quarter ended September 30, 2025. The increase was driven primarily by personnel-related expenses, including stock-based compensation.
•
Net Loss. Net loss was $21.2 million, or $0.89 per share, for the quarter ended September 30, 2026, compared to a net loss of $6.6 million, or $1.68 per share, for the quarter ended September 30, 2025.

 

About LeonaBio

 

LeonaBio, headquartered in the Seattle, Washington area, is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS), with the goal of improving patients’ lives. Our lead drug candidates, lasofoxifene and brelgometon (ATH-1105), are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. With a strong commitment to scientific excellence and patient-centered innovation, we are dedicated to developing meaningful new therapies for those who need them most.

 

For more information, visit www.leonabio.com.

 

Forward-Looking Statements

 

This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding: the beneficial characteristics, safety and efficacy of LeonaBio’s drug candidates; the potential of LeonaBio to complete the Phase 3 ELAINE-3 clinical trial for lasofoxifene and to meet the trial endpoints, the potential of ELAINE-3 to serve as a registrational trial, and any subsequent clinical trials to show the clinical benefits of lasofoxifene to the satisfaction of the FDA to support its regulatory approval; the potential of any subsequent clinical trials to show the beneficial characteristics, safety and efficacy of brelgometon; LeonaBio’s drug candidates as potential treatments for metastatic breast cancer, amyotrophic lateral sclerosis and other diseases; LeonaBio’s future development plans and the timing thereof; the potential learnings from preclinical studies and other nonclinical data and their ability to inform and improve future clinical development plans; the markets for LeonaBio’s drug candidates, if approved for commercial use, and LeonaBio’s ability to serve those markets; anticipated development milestone timelines, such as the initiation of clinical trials, the completion of enrollment in the Phase 3 ELAINE-3 clinical trial and the timing of data releases, and LeonaBio’s ability to meet such timelines; LeonaBio’s ability to obtain and maintain regulatory approval of its drug candidates in the United States and other jurisdictions and the timing thereof, and any related restrictions, limitations or warnings in the label of any approved drug candidate; LeonaBio’s regulatory, manufacturing and commercial readiness activities; LeonaBio’s ability to commercialize any approved products; and the sufficiency of LeonaBio’s capital resources to advance both its oncology and neurodegeneration programs. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as


 

“may,” “will,” “should,” “on track,” “would,” “expect,” “plan,” “believe,” “intend,” “pursue,” “continue,” “suggest,” “potential,” “target” and similar expressions. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the possible failure to realize certain anticipated benefits of the license relating to lasofoxifene and the recent private placement financing, including with respect to future financial and operating results; the data from preclinical and clinical trials may not support the safety, efficacy and tolerability of LeonaBio’s drug candidates; development of drug candidates may cease or be delayed; regulatory authorities could object to protocols, amendments and other submissions; future potential regulatory milestones for drug candidates, including those related to current and planned clinical studies, may be insufficient to support regulatory submissions or approval; whether LeonaBio’s trials are sufficiently powered to meet the planned endpoints; LeonaBio may not be able to recruit sufficient patients for its clinical trials or complete enrollment within anticipated timelines; the outcome of legal proceedings that may in the future be instituted against LeonaBio, its directors and officers; possible negative interactions of LeonaBio’s drug candidates with other treatments; FDA regulatory delays and uncertainty and new policies, including executive orders, changes in the leadership of federal agencies such as the FDA and SEC, staff layoffs, budget cuts to agency programs and research and changes in drug pricing controls; LeonaBio’s assumptions regarding its financial condition and the sufficiency of its cash, cash equivalents and investments to fund its planned operations may be incorrect; adverse conditions in the general domestic and global economic markets, including as a result of tariffs; the impact of competition; the impact of drug candidate development and clinical activities on operating expenses; the impact of new or changing laws and regulations; as well as the other risks detailed in LeonaBio’s filings with the SEC from time to time. These forward-looking statements speak only as of the date hereof and LeonaBio undertakes no obligation to update forward-looking statements. LeonaBio may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.

 

Investor & Media Contact:

Julie Rathbun

LeonaBio

julie.rathbun@leonabio.com

206-769-9219

 

 

 

 

 


 

LeonaBio, Inc.

Condensed Consolidated Balance Sheets

(Amounts in thousands)

(unaudited)

 

 

 

September 30,

 

 

December 31,

 

 

 

2026

 

 

2025

 

Assets

 

 

 

 

 

 

  Cash and cash equivalents

 

$

16,336

 

 

$

69,276

 

  Short-term investments

 

 

15,974

 

 

 

19,055

 

  Other short-term assets

 

 

4,023

 

 

 

1,127

 

  Other long-term assets

 

 

1,803

 

 

 

2,693

 

Total assets

 

$

38,136

 

 

$

92,151

 

Liabilities and stockholders' equity

 

 

 

 

 

 

  Current liabilities

 

$

7,328

 

 

$

10,015

 

Sermonix pre-funded warrant

 

 

—

 

 

 

37,488

 

Milestone liability

 

 

13,951

 

 

 

15,116

 

Long-term liabilities

 

 

840

 

 

 

1,742

 

Total liabilities

 

 

22,119

 

 

 

64,361

 

Stockholders' equity

 

 

16,017

 

 

 

27,790

 

Total liabilities and stockholders' equity

 

$

38,136

 

 

$

92,151

 

 

 

 


 

 

LeonaBio, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Amounts in thousands, except share and per share amounts)

(Unaudited)

 

 

 

Three Months Ended September 30,

 

 

 

2026

 

 

2025

 

Operating expenses:

 

 

 

 

 

 

Research and development

 

$

15,015

 

 

$

2,825

 

Milestone liability change in fair value

 

 

(411

)

 

 

—

 

General and administrative

 

 

6,863

 

 

 

4,049

 

Total operating expenses

 

 

21,467

 

 

 

6,874

 

Loss from operations

 

 

(21,467

)

 

 

(6,874

)

Other income, net

 

 

303

 

 

 

263

 

Net loss

 

$

(21,164

)

 

$

(6,611

)

Unrealized gain (loss) on available-for-sale securities

 

 

(3

)

 

 

1

 

Comprehensive loss attributable to common stockholders

 

$

(21,167

)

 

$

(6,610

)

Net loss per share attributable to common stockholders,
   basic and diluted

 

 

(0.89

)

 

 

(1.68

)

Weighted-average shares used in computing net loss per
   share attributable to common stockholders, basic
   and diluted

 

 

23,740,719

 

 

 

3,943,887

 

 

 

 

 

 


Filing Exhibits & Attachments

2 documents

Keep reading